Evaluation of enterochromaffin-like cell hyperplasia can help categorize patients with Helicobacter -negative atrophic gastritis
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae159 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Feidi Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, US. Hauptthemen laut MEDLINE: Gastritis, Atrophic, Enterochromaffin-like Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Objectives
Atrophic gastritis (AG) is characterized by atrophy of gastric glands—in particular, oxyntic glands—in the setting of chronic inflammation; it is often autoimmune. The diagnosis is confirmed by immunohistochemistry (IHC) for gastrin (to confirm biopsy site), and pathologists often use IHC for neuroendocrine markers to evaluate for enterochromaffin-like cell hyperplasia (ECL-H). The utility of neuroendocrine staining is unclear, and we undertook this study to determine whether ECL pattern provided any additional information in cases of Helicobacter-negative AG.
Methods
We reviewed clinicopathologic findings in 184 cases from 184 patients with histologic AG and no evidence of Helicobacter infection. Using neuroendocrine IHC markers, cases were divided into 3 groups: Group 1 showed complete ECL-H (both qualitative and quantitative criteria met), group 2 showed focal ECL-H (qualitative but not quantitative criteria met), and group 3 showed no ECL-H (neither criteria met).
Results
Group 1 patients were more likely to have positive autoantibody serologies (73%, P = .0007 vs group 2) and higher mean gastrin levels (700 pg/mL, P = .017 vs group 3), and only these patients developed gastric neuroendocrine tumors. Group 2 patients were more likely to take proton pump inhibitors (64%, P = .0002 vs group 1). Group 3 patients were more likely to be male (70%, P = .008 vs group 1) and to have microcytic anemia (44%, P = .022 vs group 2) and less likely to have intestinal metaplasia (50%, P = .044 vs group 1).
Conclusions
Stratification based on degree of ECL-H is not necessary for diagnosis of AG but does lead to statistically significant clinical and pathologic differences among groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, US.
- Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, US.
ORCID-Profile: Raul S Gonzalez
Zitieren
APA
Chen, F., & Gonzalez, R. S. (2025). Evaluation of enterochromaffin-like cell hyperplasia can help categorize patients with Helicobacter -negative atrophic gastritis. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae159
Vancouver
Chen F, Gonzalez RS. Evaluation of enterochromaffin-like cell hyperplasia can help categorize patients with Helicobacter -negative atrophic gastritis. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae159
BibTeX
@article{Chen2025,
author = {Chen, Feidi and Gonzalez, Raul S},
title = {Evaluation of enterochromaffin-like cell hyperplasia can help categorize patients with Helicobacter -negative atrophic gastritis},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae159}
}
EUVIMED